ArticleFrontiers in microbiology2019
Crucial Role of Microbiota in Experimental Psoriasis Revealed by a Gnotobiotic Mouse Model.
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Characterization of the Gut Microbiota in Patients with Psoriasis: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Mapping the global research landscape on psoriasis and the gut microbiota: visualization and bibliometric analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index.Scientific reports · 2020Pooled it
- Gut-derived genistein fromGut microbes · 2026Article
- Gnotobiology: from 19th-century global foundations to 21st-century omics - six decades of Czech contribution to microbiome research.Folia microbiologica · 2026Review
- Gnotobiotic mouse models as tools for dissecting the role of the microbiota in allergy: contributions from the laboratory of gnotobiology in Nový Hrádek.Folia microbiologica · 2026Review
- Gut Microbiota in Psoriasis: Evidence for Dysbiosis, Pathological Mechanisms, Causality, and Therapeutic Implications.Clinical, cosmetic and investigational dermatology · 2026Review
- Microbial Signatures of Obesity-Aggravated Psoriasis: Insights from an Imiquimod-Based Mouse Model.International journal of molecular sciences · 2025Article
- The double-edged sword: impact of antibiotic use on immunotherapy efficacy in advanced hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Psoriasis and gut microbes: research advances from mechanism to therapy.Frontiers in microbiology · 2025Review
- Exploring the Therapeutic and Gut Microbiota-Modulating Effects of Qingreliangxuefang on IMQ-Induced Psoriasis.Drug design, development and therapy · 2025Article
- Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis.ACS pharmacology & translational science · 2024Article
- Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.Journal of personalized medicine · 2024Review
- Bifidobacteria in disease: from head to toe.Folia microbiologica · 2024Review
- A Novel Multi-Strain E3 Probiotic Formula Improved the Gastrointestinal Symptoms and Quality of Life in Chinese Psoriasis Patients.Microorganisms · 2024Article
- Genetic background and microbiome drive susceptibility to epicutaneous sensitization and food allergy in adjuvant-free mouse model.Frontiers in immunology · 2024Article
- The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Investigating the gut microbiota's influence on psoriasis and psoriatic arthritis risk: a Mendelian randomization analysis.Precision clinical medicine · 2023Article
- Insights into Nutritional Strategies in Psoriasis.Nutrients · 2023Review
- Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity.Immunity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic patients have altered microbiota, both in the intestine and on the skin. It is not clear, however, whether this is a cause or consequence of the disease. In this study, using an experimental mouse model of psoriasis induced by imiquimod (IMQ), we show that oral treatment with a broad spectrum of antibiotics (MIX) or metronidazole (MET) alone mitigates the severity of skin inflammation through downregulation of Th17 immune response in conventional mice. Since some antibiotics, including MET, can influence immune system reactivity, we also evaluated the effect of MIX in the same model under germ-free (GF) conditions. GF mice treated with MET did not show milder signs of imiquimod-induced skin inflammation (IISI) which supports the conclusion that the therapeutic effect is mediated by changes in microbiota composition. Moreover, compared to controls, mice treated with MIX had a significantly higher abundance of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.